NCT05421767 Renal Nerve Stimulation in Uncontrolled Hypertensive Patients Undergoing Renal Denervation
| NCT ID | NCT05421767 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | National Taiwan University Hospital |
| Condition | Hypertension |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2022-06-24 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 60 participants in total. It began in 2022-06-24 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Study design: Investigator initiated, single center The study is aimed 1\) To investigate the blood pressure (BP) change to renal nerve stimulation(RNS), and subsequently perform a renal denervation(RDN) procedure 1\) to verify the cutoff value (RNS-induced systolic BP change \<20 mmHg in post-RDN patients) could be a useful clinical endpoint in RDN therapy, and test the hypothesis that intense RDN could improve the efficacy of RDN.
Eligibility Criteria
Inclusion Criteria: Patients with hypertension (HTN), including 1. 24-hour ambulatory blood pressure \>130/ 80 mmHg 2. Age 20-80 years 3. Glomerular filtration rate \>45 mL/min Exclusion Criteria: 1. Unsuitable renal artery anatomy computed tomographic angiography (main renal artery lumen diameter ≤3 mm or a total length \<20 mm of the main arteries). 2. untreated secondary HTN, including hyperaldosteronism, pheochromocytoma, renal artery stenosis(\>50% stenosis)
Frequently Asked Questions
Who can join the NCT05421767 clinical trial?
This trial is open to participants of all sexes, aged 20 Years or older, studying Hypertension. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT05421767 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT05421767 currently recruiting?
Yes, NCT05421767 is actively recruiting participants. Visit ClinicalTrials.gov or contact National Taiwan University Hospital to inquire about joining.
Where is the NCT05421767 trial being conducted?
This trial is being conducted at Taipei, Taiwan.
Who is sponsoring the NCT05421767 clinical trial?
NCT05421767 is sponsored by National Taiwan University Hospital. The trial plans to enroll 60 participants.